Cyclerion Therapeutics Net Worth
Cyclerion Therapeutics Net Worth Breakdown | CYCN |
Cyclerion Therapeutics Net Worth Analysis
Cyclerion Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cyclerion Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cyclerion Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cyclerion Therapeutics' net worth analysis. One common approach is to calculate Cyclerion Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cyclerion Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cyclerion Therapeutics' net worth. This approach calculates the present value of Cyclerion Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cyclerion Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cyclerion Therapeutics' net worth. This involves comparing Cyclerion Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cyclerion Therapeutics' net worth relative to its peers.
To determine if Cyclerion Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cyclerion Therapeutics' net worth research are outlined below:
| Cyclerion Therapeutics had very high historical volatility over the last 90 days | |
| Cyclerion Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2 M. Net Loss for the year was (3.06 M) with profit before overhead, payroll, taxes, and interest of 2 M. | |
| Cyclerion Therapeutics currently holds about 30.32 M in cash with (4.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7. | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Higgins Michael J of 9090 shares of Cyclerion Therapeutics at 2.75 subject to Rule 16b-3 |
Cyclerion Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cyclerion Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cyclerion Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Cyclerion Therapeutics Target Price Consensus
Cyclerion target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cyclerion Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Cyclerion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cyclerion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cyclerion Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCyclerion Therapeutics Target Price Projection
Cyclerion Therapeutics' current and average target prices are 2.68 and 4.00, respectively. The current price of Cyclerion Therapeutics is the price at which Cyclerion Therapeutics is currently trading. On the other hand, Cyclerion Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Cyclerion Therapeutics Market Quote on 2nd of April 2025
Target Price
Analyst Consensus On Cyclerion Therapeutics Target Price
Know Cyclerion Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cyclerion Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cyclerion Therapeutics backward and forwards among themselves. Cyclerion Therapeutics' institutional investor refers to the entity that pools money to purchase Cyclerion Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Group One Trading, Lp | 2024-12-31 | 540 | Mccormack Advisors International | 2024-12-31 | 100.0 | Activest Wealth Management | 2024-12-31 | 100.0 | Zrc Wealth Management, Llc | 2024-12-31 | 20.0 | Bank Of America Corp | 2024-12-31 | 19.0 | Sbi Securities Co Ltd | 2024-12-31 | 11.0 | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 5.0 | Northwestern Mutual Wealth Management Co | 2024-12-31 | 1.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Tyndall Capital Partners L P | 2024-12-31 | 164.8 K | Tyndall Management, Llc | 2024-12-31 | 164.8 K |
Follow Cyclerion Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.54 M.Market Cap |
|
Project Cyclerion Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.41) | (0.39) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.35) | (0.33) |
When accessing Cyclerion Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cyclerion Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cyclerion Therapeutics' profitability and make more informed investment decisions.
Evaluate Cyclerion Therapeutics' management efficiency
Cyclerion Therapeutics has return on total asset (ROA) of (0.1976) % which means that it has lost $0.1976 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3036) %, meaning that it created substantial loss on money invested by shareholders. Cyclerion Therapeutics' management efficiency ratios could be used to measure how well Cyclerion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of April 2025, Return On Tangible Assets is likely to drop to -0.34. In addition to that, Return On Capital Employed is likely to grow to -0.39. At this time, Cyclerion Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 2nd of April 2025, Asset Turnover is likely to grow to 0.20, while Total Assets are likely to drop about 9.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.51 | 3.34 | |
| Tangible Book Value Per Share | 3.51 | 3.34 | |
| Enterprise Value Over EBITDA | (1.34) | (1.41) | |
| Price Book Value Ratio | 0.92 | 0.96 | |
| Enterprise Value Multiple | (1.34) | (1.41) | |
| Price Fair Value | 0.92 | 0.96 | |
| Enterprise Value | 4.4 M | 3.9 M |
Cyclerion Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 1.5664 | Revenue | Quarterly Revenue Growth 0.141 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclerion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclerion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyclerion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cyclerion Therapeutics Corporate Filings
| 28th of March 2025 Other Reports | ViewVerify | |
F4 | 27th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 25th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 4th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Cyclerion Therapeutics Earnings per Share Projection vs Actual
Cyclerion Therapeutics Corporate Management
| Todd Milne | Senior Innovation | Profile | |
| Cheryl Gault | Chief Officer | Profile | |
| Jessica Rennekamp | Associate Communications | Profile | |
| Rhonda CPA | Chief Officer | Profile | |
| Christopher Winrow | Sr Lead | Profile | |
| Jennifer Chickering | Director Strategy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.21) | Revenue Per Share | Quarterly Revenue Growth 0.141 | Return On Assets | Return On Equity |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.